The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
|
|
||
![]() |
||
CRIXIVAN® (indinavir sulfate) in combination with other antiretroviral agents is indicated for the treatment of HIV infection. This indication is based on 2 clinical trials of approximately 1 year’s duration that demonstrated (1) a reduction in the risk of AIDS-defining illness or death and (2) a prolonged suppression of HIV RNA.
CRIXIVAN:
CRIXIVAN is contraindicated in patients with clinically significant hypersensitivity to any of its components.